Structural Identification of Modified Amino Acids on the Interface between EPO and Its Receptor from EPO BRP, Human Recombinant Erythropoietin by LC/MS Analysis |
Song, Kwang-Eun
(Department of Stereoscopic Media, Korean German Institute of Technology)
Byeon, Jaehee (Department of Stereoscopic Media, Korean German Institute of Technology) Moon, Dae-Bong (BIOnSYSTEMS, Inc., R&D Center) Kim, Hyong-Ha (Center for Bioanalysis, Korea Research Institute of Standards and Science) Choi, Yoo-Joo (Department of Newmedia, Korean German Institute of Technology) Suh, Jung-Keun (Department of Newmedia, Korean German Institute of Technology) |
1 | Brines, M., Patel, N.S., Villa, P., Brines, C., Mennini, T., De Paola, M., Erbayraktar, Z., Erbayraktar, S., Sepodes, B., Thiemermann, C., et al. (2008). Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc. Natl. Acad. Sci. USA 105, 10925-10930. DOI ScienceOn |
2 | Davis, J.M., Arakawa, T., Strickland, T.W., and Yphanitis, D.A. (1987). Characterization of recombinant human erythropoietin produced in Chinese hamster ovary cells. Biochemistry 26, 2633-2638. DOI ScienceOn |
3 | Chang, S.H., Kim, H.J., and Kim, C.W. (2013). Analysis of the structure and stability of erythropoietin by pH and temperature changes using various LC/MS. Bull. Korean Chem. Soc. 34, 2663-2670. 과학기술학회마을 DOI ScienceOn |
4 | Cheetham, J.C., Smith, D.M., Aoki, K.H., Stevenson, J.L., Hoeffel, T.J., Syed, R.S., Egrie, J., and Harvey, T.S. (1998). NMR structure of human erythropoietin and a comparison with its receptor bound conformation. Nat. Struct. Biol. 5, 861-866. DOI ScienceOn |
5 | Delorme, E., Lorenzini, T., Giffin, J., Martin, F., Jacobsen, F., Boone, T., and Elliott, S. (1992). Role of glycosylation on the secretion and biological activity of erythropoietin. Biochemistry 31, 9871-9876. DOI ScienceOn |
6 | Elliott, S., Lorenzini, T., Chang, D., Barzilay, J., and Delorme, E. (1997). Mapping of the active site of recombinant human erythropoietin. Blood 89, 493-502. |
7 | Eschbach, J.W., Abdulhadi, M.H., Browne, J.K., Delano, B.G., Downing, M.R., Egrie, J.C., Evans, R.W., Friedman, E.A., Graber, S.E., Haley, N.R., et al. (1989). Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann. Intern. Med. 111, 992-1000. DOI ScienceOn |
8 | Gan, Y., Xing, J., Jing, Z., Stetler, R.A., Zhang, F., Luo, Y., Ji, X., Gao, Y., and Cao, G. (2012). Mutant erythropoietin without erythropoietic activity is neuroprotective against ischemic brain injury. Stroke 43, 3071-3077. DOI |
9 | Greer, F., Reason, A., and Rogers, M. (2002). Post-translational modifications of biopharmaceuticals-a challenge for analytical characterisation. Eur. Biopharm. Rev. 106-111. |
10 | Lodish, H.F., Hilton, D.J., Klingmuller, U., Watowich, S.S., and Wu, H. (1995). The erythropoietin receptor: biogenesis, dimerization, and intracellular signal transduction. Cold Spring Harb. Symp. Quant. Biol. 60, 93-104. |
11 | Syed, R.S., Reid, S.W., Li, C., Cheetham, J.C., Aoki, K.H., Liu, B., Zhan, H., Osslund, T.D., Chirino, A.J., Zhang, J., et al. (1998). Efficiency of signaling through cytokine receptors depends critically on receptor orientation. Nature 395, 511-516. DOI ScienceOn |
12 | Toyoda, T., Itai, T., Arakawa, T., Aoki, K.H., and Yamaguchi, H. (2000). Stabilization of human recombinant erythropoietin through interactions with the highly branched N-glycans. J. Biochem. 128, 731-737. DOI ScienceOn |
13 | Walsh, G. (2010). Post-translational modifications of protein biopharmaceuticals. Drug Discov. Today 15, 773-780. DOI ScienceOn |
14 | Winearls, C.G., Oliver, D.O., Pippard, M.J., Reid, C., Downing, M.R., and Cotes, P.M. (1986). Effect of human etythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 328, 1175-1178. DOI ScienceOn |
15 | Brinks, V., Hawe, A., Basmeleh, A.H., Joachin-Rodriguez, L., Haseberg, R., Somsen, G.W., Jiskoot, W., and Schellekens, H. (2011). Quality of original and biosimilar epoetin products. Pharm. Res. 28, 386-393. DOI |